article thumbnail

India IT ministry releases draft rules under controversial data legislation

JURIST

India’s Ministry of Electronics and Information Technology (MeitY) on Saturday released draft rules in furtherance of the Digital Personal Data Protection (DPDP) Act, sparking significant debate regarding the rules’ implications on data privacy rights.

Drafting 104
article thumbnail

Small Change: FDA’s Final Predetermined Change Control Plan (PCCP) Guidance Ditches ML and Adds Some Details, But Otherwise Sticks Closely to the Draft

FDA Law Blog

The final guidance hasnt changed much from the draft guidance with respect to the type of modifications FDA considers applicable for a PCCP and the required components of a PCCP (see our prior blog post on the draft guidance here ). FDA may request additional information during the review of the PCCP.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The ICH E6(R3) Guideline: A Major Update to Good Clinical Practice

FDA Law Blog

While ICH E6(R3) was still in the development phase, the FDA released a draft guidance in May 2023 in the form of the draft ICH E6(R3). Livornese As anticipated, the International Council for Harmonization (ICH) published the Good Clinical Practice (GCP) guideline E6(R3) Principles and Annex 1 on January 6, 2025.

article thumbnail

Change is Inevitable – Plan Ahead: An Assessment of FDA’s Draft Guidance on Predetermined Change Control Plans for Artificial Intelligence/Machine Learning-Enabled Device Software Functions

FDA Law Blog

Javitt — FDA recently published a long-awaited draft guidance aimed at reducing the need for prior FDA authorization of modifications to artificial intelligence/machine learning (AI/ML)-enabled device software functions (ML-DSFs). The draft guidance follows the December 2022 enactment of the Food and Drug Omnibus Reform Act of 2022 (FDORA).

article thumbnail

Clinical Trials Join the Remote Work Revolution: FDA’s New Draft Guidance on Decentralized Clinical Trials

FDA Law Blog

Cato — On May 2nd, FDA released a new draft guidance with recommendations for decentralized clinical trials (DCTs) for drugs, biologics, and devices. This draft guidance builds on recommendations that FDA initially developed early in 2020, in response to the COVID-19 challenges (see our blog post on these recommendations here ).

article thumbnail

Knock, Knock – FDA Issues Guidance on Best Processes and Practices During BIMO Inspections

FDA Law Blog

In an effort to clarify for industry and alleviate some of the stress associated with these activities, last week the FDA issued a draft guidance aimed at providing recommendations on how to handle inspections under FDA’s Bioresearch Monitoring (BIMO) program. 11-12 of the guidance for a list of these resources).

Drafting 111
article thumbnail

The Top 8 Gavel Alternatives for Faster, Smarter Legal Document Automation

Knackly

Pricing Lite $83/month (1 builder seat, 10 templates, basic automation) Standard $210/month (1 builder seat, 50 templates, data management, integrations) Pro $290/month (2 builder seats, 100 templates, Stripe payments, custom branding) Scale Starts at $417/month (custom usage, API access, SSO, dedicated support) Why Look for a Gavel Alternative?